SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), today reported on its financial results for the third quarter ended September 30, 2016, and schedules a conference call to provide both a business and financial update on Monday, November 14, 2016, after the close of the U.S. financial markets. Below are details for the call.
Business Update on Interim Results of Clinical Trials and New Patent
“We look forward to disclosing on Monday the progress that we have been making with both our clinical trials of our lead antibody development program,” stated President and CEO, J. David Hansen. “Specifically, we will be talking about interim phase I clinical results of MVT-5873 as a therapeutic antibody for pancreatic cancer and other malignancies that express the same target antigen present on many gastrointestinal cancers. We will also share our progress in evaluating the use of MVT-2163 as an immuno-PET imaging agent. And we will explain the significance of being issued a patent by the United States Patent and Trademark Office for our fully-human monoclonal antibody that forms the basis for both our MVT-5873 and MVT-2163 clinical development programs.”
